Atrial-Fixation TMVR Appears Feasible, Durable at 1 Year
The AltaValve system, featuring a novel atrial fixation mechanism, shows promise for high-risk patients undergoing transcatheter mitral valve replacement (TMVR). An early feasibility study demonstrated significant reductions in mitral regurgitation and improved clinical outcomes at one year. The device aims to expand access to TMVR for patients who are typically ineligible for conventional procedures due to anatomical challenges.
- ▪The AltaValve system was tested in a study involving 30 high-risk patients across Europe, the US, and Japan.
- ▪At one year, all patients had none or trace regurgitation immediately post-procedure, with 95% maintaining mild or trace regurgitation.
- ▪The study reported no new-onset atrial fibrillation or stroke in either patient group during the follow-up period.
Opening excerpt (first ~120 words) tap to expand
High-risk patients treated with the AltaValve system, which employs a novel atrial fixation mechanism, had sustained reductions in mitral regurgitation at 1 year and improved clinical outcomes in an early feasibility study. The company hopes the device will make transcatheter mitral valve replacement (TMVR) accessible to more patients, including those who would not be eligible for conventional TMVR.When Subvalvular TMVR Falls ShortSurgery and guideline-directed medical therapy remain the standard of care for mitral regurgitation, but mitral transcatheter edge-to-edge repair (mTEER) has become a preferred option for patients at high surgical risk or with refractory heart failure.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
